Curriculum Vitae Page 1

EDUCATION:
Doctor of Medicine
University of Miami, School of Medicine
Miami, FL
1981 to 1985
Bachelor of Science, Humanities Program
Davidson College
Davidson, NC
1977-1981
POST GRAD TRAINING:
Interventional Cardiology: Advanced Interventional Fellowship
Washington Hospital Center
Washington D.C.
1993-1994
Interventional Cardiology: US Navy
St. Mary’s Hospital Center,
San Francisco, CA
1990-1991
Cardiology: Fellowship
Columbia University, College of Physicians and Surgeons
St. Luke’s—Roosevelt Hospital Center
New York, NY
1988-1990
Internal Medicine: Internship and Residency
Columbia University, College of Physicians and Surgeons
St. Luke’s—Roosevelt Hospital Center
New York, NY
1985-1988
EXPERIENCE:
Sutter Health, Valley Region, Medical Director, Cardiovascular Services Sutter Health Sacramento Sierra Region
Sacramento, CA
2013 to Present
Medical Director, Cardiovascular Services
Sutter Medical Group
Sacramento, CA
2010 to Present
Research Committee Member
Sutter Institute for Medical Research
Sacramento, CA
1997 to Present
Medical Director, Cardiac Catheterization Laboratory
Sutter Medical Center
Sacramento, CA
2001– 2015
Medical Director, Sutter Heart& Vascular Institute
(Position Expanded to Regional Directorship)
Sutter Medical Center
Sacramento, CA
2008 to 2013
Sutter Heart & Vascular Services
2800 L Street, 6th Floor
Sacramento, CA 958196
Office:887-4040
Email: robertdk@sutterhealth.org
David K. Roberts, MD, FACC, FSCAI
Cardiovascular Services
California State License
No. G070643
Research Office
Sutter Institute for Medical Research
2801 Capitol Avenue Suite 210
Sacramento, CA 95816
Office: (916) 887-4698
Fax: (916) 887-4751
Curriculum Vitae Page 2
Updated 07/2022
EXPIRENCE CONT.:
Executive Member, Governor's Council on Peripheral Artery Disease
State of California
2010 to 2011
Chief, Medical Staff Cardiovascular Department
Sutter Medical Center
Sacramento, CA
2004-2006
Vice Chief, Medical Staff Cardiovascular Department
Sutter Medical Center
Sacramento, Ca
2002-2004
Executive Committee, Medical Staff Cardiovascular Department
Sutter Medical Center
Sacramento, Ca
1998 to Present
Executive Committee, Medical Staff Cardiovascular Department
Mercy General Hospital
Sacramento, CA
1998 to 2006
American Heart Association
Executive Board, California Affiliate
Sacramento, CA
1997 to 2003
Institutional Review Board
Sutter Institute for Medical Research, Sutter Community Hospitals
Sacramento, CA
1996 to 2001
Myocardial Infarction Committee
Sutter Community Hospitals
Sacramento, CA
1994 to 1998
Partner
Sacramento Heart & Vascular Medical Associates
Sacramento, CA
1994 to 2010
Junior Associate, Washington Cardiology Center
Washington Hospital Center
Washington D.C
1993 to 1994
Director
Cardiac Catheterization Laboratory
Oakland, CA
1990 to 1993
David K. Roberts, MD, FACC, FSCAI
Curriculum Vitae Page 3
Updated 07/2022
EXPIRENCE CONT.:
Staff Cardiologist, Courtesy
St. Mary’s Hospital
San Francisco, CA
1991 to 1993
Consultant Cardiologist
Silas B Hayes Army Hospital
Fort Ord, CA
1991 to 1993
BOARD CERTIFICATIONS:
• American Board of Internal Medicine, Subspeciality lnterven1ional, 1999
• Cardiology American Board of Internal Medicine, Subspeciality, 1991
• Cardiovascular Diseases American Board of Internal Medicine, 1989 American Board of Medical Examiners, 1986
AWARDS:
• Alpha Epsilon Delta: Honor Society, 1981
• U.S. Navy Health Professional Scholarship, 1981
PROFESSIONAL SOCIETIES:
• American College of Cardiology Fellow, 1992 to Present
• American College of Cardiology Affiliate, 1988 to 1992
• Society for Cardiovascular Angiography & Interventions Fellow, 2006 to Present
• American College of Physicians Associate, 1987-1990
MILITARY SERVICE:
• U.S. Navy Reserve (Honorable Discharge), 1981 to 1994
• Active Duty, LCDR, Medical Corps, USNR, 1990 to 1993
UNIVERSITY AFFILATION:
Assistant Clinical Professor of Medicine
University of California, Davis
1995 to 1999
EDITIONAL BOARD:
• Interventional Cardiology Bulletin, 1997 to 1999
MEDICAL LICENSES:
• State of New York (Inactive), 1986
• State of California, 1991
• District of Columbia (Inactive), 1993

HOSPITAL AND CLINICAL APPOINTMENTS:
Sutter Community Hospitals:
• Active Staff Department of Medicine, Cardiology Section, SMCS, 1994 to Present
• Sutter Davis (Courtesy), 1998 to Present
• Sutter Roseville (Courtesy), 1999 to Present
Mercy Community Hospitals:
• Active Staff, Department of Medicine, Cardiology Section, Mercy General Sacramento, 1994 to 2010
• Methodist Hospital (Courtesy), 1995 to 2010
• Woodland Memorial Hospital (Courtesy), 2002 to 2010
• Mercy San Juan (Courtesy), 1995 to 2002
• Mercy American River (Courtesy), 1995 to 2002
• Mercy Folsom (Courtesy), 1995 to 2002
David K. Roberts, MD, FACC, FSCAI
Curriculum Vitae Page 5
Updated 07/2022
HOSPITAL AND CLINICAL APPOINTMENTS CONT.:
University of California Davis Medical Center:
• Department of Medicine, Cardiology Section (Courtesy) , 1995 to 1999
Marshall Hospital:
• Consultant Cardiologist, Department of Medicine, 1997 to 2003
ADVANCED INTERVENTIOAL CARDIOLOGY PROCEDURES:
• Watchman Left Atrial Exclusion
• Percutaneous Valve Replacement (Mitral, Pulmonic, Tricuspid)
• MitraClip-Percutaneous Mitra! Valve Repair
• Transcatheter Aortic Valve ReplacementTAVR (Trans Apical and FemmaJ
• Edwards Sapien & Cor Valve
• Percutaneous Cardiac (Aortic & Mitra1) Valvuloplasty
• AAA Endovascular Repair
• Alcohol Septa! Ablation
• Coronary and Carotid Interventions with Distal (Occlusive & Filter) Protection
• Carotid Stenting
• Carotid & Cerebral Angiography
• Percutaneous Atrial Septal and Patent Foramen Ovale Closure
• Percutaneous Ventricular Septal Closure
• Percutaneous Atrial Septa) and Patent Foramen Ovale Closure Percutaneous Ventricular Septal Closure
• Peripheral Vascular Interventions:/Angioplosty/Stenting/Atherectomy/Laser/Thrombectomy Radiation Brachytherapy
• Intracardiac& Intravascular Coronary Ultrasound
• Percutaneous Transluminal Rotational Atherectomy
• Coronary $tenting (Including Medicated Stent Implantation)
• Directional Coronary Atherectomy
• Transluminal Extraction Coronary Atherectomy
• Coronary Thrombectomy
• Excimer Laser Coronary Angioplasty
• Coronary (Angiojet) Thrombectomy
FDA APPROVED COURSES FOR ADVANCED CORONARY INTERVENTIONS:
• Melody Percutaneous Pulmonic Valve ( Columbus OH), 2017
• Watchman Left Atrial Appendage Occlusion ( Los Angeles, CA), 2016
• Abbott MitraClip ( Santa Clara, CA), 2015
• Medtronic Aortic CorValve-TAVR ( Los Angeles, CA) ,2014
• Left Atrial Appendage Occ!usion-Amplatze1( Minneapolis. MN), 2013
• Renal Denervation St Jude ( San Francisco, CA) , 2013
• Edwards Sapien Aortic Valve-TAVR transfemoral approach (Vancouver, BC), 2012
• Edwards Sapien Aortic Valve-TA VR Apical approach (Irvine, CA), 2012
• Endologix AAA Endovascular Repair (Houston, TX) , 2008
• Gore AAA Endovascular Repair (USC, Los Angeles. CA), 2008
• Foxhollow Atherectomy (Chicago, JI), 2003
• Novoste Beta Brachytherapy ( Atlanta, GA), 2000
• Cordis Gamma Brachytherapy (San Diego, CA), 2000 Wiktor Coronary Stent {New Orleans, LA) , 1997
David K. Roberts, MD, FACC, FSCAI
Curriculum Vitae Page 6
Updated 07/2022
FDA APPROVED COURSES FOR ADVANCED CORONARY INTERVENTIONS CONT.:
• Multilink Stent (Santa Clara, CA), 1997
• Excimer Laser Coronary Angioplasty (Washington, D.C.), 1995
• Cook Coronary Stent (Washington, D.C.), 1994
• Transluminal Extraction Coronary Atherectomy {Atlanta, GA), 1994
• Johnson & Johnson Coronary Stent (Washington, D.C.), 1994
• Rotational Coronary Atherectomy (San Diego, CA) , 1994
• Directional Corona1y Atherectomy (Washington, D.C.) , 1993
PUBLICATIONS:
• David Roberts, KhuSrow Niazi, William Miller, Prakash Krishnan, Roger Gammon, Theodore Schreiber, Nicolas W. Shammas Daniel Clair. “Effective Endovascular Treatment of Calcified Femoropopliteal Disease with Directional Atherectomy and Distal Embolic Protection: Final Results of the DEFJNITJVE CA++ Trial. Catheterization and Cardiovascular Interventions” 2014; 84: 236-244.
• Clair, D.G. and Roberts D.K. “Treatment of Servilely Calcified Femoropopliteal Lesions with Plaque Excision and Embo!ic Protection-DEFINITIVE Ca++.” J Vase lnten1 Radiol 2011 :22: I 785.e2
• David R.Holmes,Jr, Paul Teirstein, Lowell Satleret. aI. for the SJSR Investigators David K Roberts. “SiroHmus-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents. The SlSR Randomized Trial.” JAMA 2006;295: 1264-1273.
• Gregg W. Stone, Bruce R. Brodie, Ronald Caputo, Robert Feklman, Campbell Rogers, David A.Cox, David K. Roberts, A. Zaki Masud, James Hennilh, Patrick Cambier, David Kovach, Manuela Negolta, Alan, “Schwartz, Ramona Pop, Martin Fahy, Roopan Sikand, Roxana Mehran. Thirty Day and Six Month Outcomes after Saphenous Vein Graft Stenting with Distal Protection in Patients Excluded from Randomized Tn.ls: The Filter Wire EX High Risk Registry.” JACC 2005; 45:83A.
• Jeffrey J. Popma et. al for the SIRIUS Investigators David K. Roberts. “ Quantitative Assessment of Angiographic Restenosis After Sirolimus-Eluting Stent implantation in Native Coronary Arteries.” Circulation 2004; 110:3773-3780.
• David J, Cohen et.al for the SIRIUS Investigators David K. Roberts. “Cost -Effectiveness of Sirolimus Eluting Stents for Treatment of Complex Coronary Stenoses, Results From the Sirolimus Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Lesions (SlRIUS) Trial.” Circulation 2004; 110:508.514.
• Shinjo Sonoda et. al for the SIR1US Investigators David K. Roberts. “Impact of Pinal Stent Dimensions on Long Term Results Following Sirolimus– Eluting Stent Implantation. Serial Intravascular Ultrasound Analysis From the SIRIUS Trials.” JACC 2004; i 1;1959•1963
• Jeffrey W. Moses, et. al for the SlRIUS Investigators David K. Roberts. “Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery.” New Eng J Med 2003; 349:131§1323.
• David K. Roberts George Emlein, Philip M. Bach, George Fehrenbacher, Beverly D. Seiler, Katherine M. Johnson, Carol A. Parise Stephens. “ Macroembolic Debris Extraction Following the Use of Occlusive Distal Protection: An In Vitro Comparison of the Angiojet and Export Catheters.” American J Cardiology 2002:90(Suppl 6A): 40H.
David K. Roberts, MD, FACC, FSCAI
Curriculum Vitae Page 7
Updated 07/2022
PUBLICATIONS CONT.:
• David K.Roberts, Ali H.M. Hassan, Katzuhiro, Jorge Luna, Ronald D.Page, George Fehrenbacher, Hassan M.Hussain, Cathy A Stephens, Peter J.Fitzgerald. “ The Impact of Noncompliant Balloon Materials on Balloon Delivered Coronary Stent Expansion.” Circulation 2000; 102:I.J547,
• Stefan Kiesz, Steven R.BaiJey, Marius M.Rosek, David K. Roberts, Timothy Sanborn, Julia M. Sepeda, Frederick G. St Goar, Tom J, Linnemeire. “Small vs Large Vessel IVUS Guided “Maximal Stenting” Improved Long Term Outcomes: The OSTI-2 Study.” Circulation 2000; 102:IJ.548.
• Gregg W. Stone, Steven Bailey, David K. Roberts, Tom J. Linnemeire, FredStGoar, Timothy Sanborn Peter J. Fitzgerald, Edwin L. Aldennan, and Stefan Kiesz. “A Prospective, Multicenter Trial of the Safety, Feasibility, and Efficacy of Ultrasound Guided "Maximal"' Stenting o the MediaAdventitial Border. Final Late Clinical and Angiographic Results from the OSTI•2 Smdy. JACC 2000 35:46A.
• Cindy L. Grines, David A. Cox, Gregg W. Stone, and the STENTPAMI Study Group* David K. Roberts. “Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction.” New Eng J Med 1999; 341:1949-1956.
• Steven Bailey, Stefan Kiesz, Tom J, Linnemeire, Geraldine M. CoopetR.eade, David K. Roberts, Fred St Goar, and Gregg W. Stone. “Stent Implantation in Small Vessels Using Ultrasound Guided Implantation: Comparison of Late Outcome of LAD and Non-LAD Lesions. JACC 1999; 33:68A.
• Gregg W. Stone, Steven Bailey. David K. Roberts. Tim Sanborn, Tom J. Linnemeire, Fred St Goar, and Stefan Kiesz. “Long-term Results Following "Maximal Stenting" Using Ultrasound Guided Focal Balloon Stent Overexpansion -The Second Optimal Stent Implantation Study.” Circulation 1998; 98:-Il 60.
• Gregg W, Stone, Stefan Kiesz, Akio Oshima, Ed Aldennan, Steve Bailey, Tim SanbornPavid K. Roberts, Paul Yock, Fred St Goar, and Tom l Linnemeire. Improved Procedural Reults of Coronary Stenting with Focal Balloon "Overexpansion"-Fina.l Core Lab Analysis from the Prospective, Multicenter OST-12A Trial. JACC 1998; 3 l:l6A.
• David K. Roberts, Editorial, “The Primary Angioplasty In Myocardial Infarction Trial.” Interventional Cardiology Bulletin. \ 997;Volume I, Number2:67.
• David K. Roberts. Arvin Arthur, Raye L. Bellinger, Philip M. Bach, George Fehrenbacher, Larry E. Berte, Lucy A Lindsey, Sheryl I. Huss. “The Impact on Coronary Stent Implantation of Intravascular Ultrasound Guidance Following "Aggressive" Angiographic Stent Implantation.” JACC 1997; 29:275A.
• Rekha Garg, Richard Gorlin, Thomas Smith, Salim Yusaf & The Digitalis lnvestigation Group: David K. Roberts et. al. “The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure.” New Eng J Med 1997; 336:525-533.
• Arvin Arthur, Raye L. Bellinger, David K. Roberts, Mark H. Eaton, Larry E. Berte, Philip M. Bach. An Easier Method of Ascertaining Whether the Balloon Catheter is Ruptured. Catheterization and Cardiovascular Diagnosis 1996; 39:214.
• David K. Roberts, Arvin Arthur, Raye L. Bellinger, James E. Lewis, Shery( I. Hass, Carol A. Parise. “Reduced Anticoagulation Protocol for Stenting (RAPS) in Smaller Coronary Vessels using Intravascular Ultrasound Guidance. 30 Day Procedural Results.” JACC 1996;
David K. Roberts, MD, FACC, FSCAI
Curriculum Vitae Page 8
Updated 07/2022
PUBLICATIONS CONT.:
• Andrew Farb, David K. Roberts, Augusto D. Pichard, Kenneth M. Kent, Renu Virmani. “Coronary Artery Morphological Features after Coronary Rotational Atherectomy: Insights into Mechanisms of Lumen Enlargement and Embolization. Am Heart J l 995 129(6): l 05& 1067.
• Jeffrey J. Popma.,David K. Roberts, Lowell F, Satler, At1gusto D. Pichard, Kenneth M. Kent, Ya Chien Chuang, Gary S. Mintz, Luela T. Lewis, Tereza Y. Conway, Martin 8. Leon. “The Need for Late T-rget Revascularization After Rotational Atherectomy is Lower in Women and in Patients with a Larger Acute Procedural Result.” JACC 1994;1:137A.
• Scott J. Ratner, David K. Roberts. “Vancomycin and Interstitial Nephrites.” American Journal of Internal Medicine J 988;84:561.
CURRECT RESEARCH PROJECTS:
• Structural Heart Disease- Percutaneous Interventions
• Percutaneous Valve Replacement Percutaneous Coronary Revascularization
• Drug Eluting Stenting/Vascular Scaffold
• Percutaneous Peripheral Vascular Revascularization
• Complete Total Occlusions Adjunctive Interventional Pharmacology
CLINICAL TRIAL PARTICIPATION:
Principle Investigator:
• PFO Occluder Post Approval Study
• Transcatheter Mitral Valve Replacement (TENDYNE)
• Feasibility of Transcatheter Aortic Valve Replacement in Low Risk Patients with Symptomatic, Severe Aortic Stenosis (Medstar Standard Risk TAVR)
• Portico Resheathable Transcatheter Aortic Valve System US IDE Trial(PORTICO)
• A randomized trial comparing the ELUVIA drug-eluting stent versus Zilver® PThr® stent for treatment of superficial femoral and/or proximal popliteal arteries (IMPERIAL)
• Clinical Evaluation of AbsorbH1 BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions (Absorb III and IV)
• Phase II Open Label, Randomized Study of the Safety, Pharmacokinetics and Preliminary Efficacy of an Anti inflammatory Therapeutic Antibody (CV18C3) in Reducing Restenosis in Patients Undergoing Percutaneous Femoropopliteal Revascularization (Xbiotech)
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Study to Evaluate the Efficacy, Safety, and Tolerability of Ixmyelocel-t in Subjects with Critical Limb Ischemia and No Options for Revascularization (Revive)
• A Prospective Chronic Total Occlusion Crossing with the Ocelot System II (CONNECT II)
• A Prospective Study using ST Monitoring to Detect ACS Events in ICD Patients (ANALYSE ST)
• A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY™ Stent System) for the Treatment of Atherosclerotic Lesions (Evolve II)
David K. Roberts, MD, FACC, FSCAI
Curriculum Vitae Page 9
Updated 07/2022
CLINICAL TRIAL PARTICIPATION CONT:
Principle Investigator:
• A Prospective Study is to evaluate the safety and effectiveness of the ACP (Amplatzer Cardiac Plug) in subjects with nonvalvular atrial fibrillation by demonstrating that the device is noninferior to optimal medical therapy (OMT) with respect to the primary effectiveness endpoint and superior to OMT with respect to primary safety endpoint.(Amplatzer Cardiac Plug)
• A Prospective Study to confirm the safety and effectiveness of the Protege® EverFlex Self-Expanding Stent System, and Protege® GPSTM Self– Expanding Nitinol Stent and Delivery Technology (Protege stents) in treating atherosclerotic disease in the common iliac and/or external mac arteries. (Durability)
• A Prospective Study to confirm the safety and effectiveness of the Visi-Pro Balloon Expandable Stent System (Visi-Pro stent) in treating atherosclerotic disease in the common iliac and/or external iliac arteries. (Visibility)
• Pivotal Study to Evaluate the Safety and Performance of Orbital Atherectomy System in Treating de novo Severely Calcified Coronary Lesions. (ORBIT II)
• A Randomized, partially-blinded, multi-Center, Active-Controlled, Dose- Ranging study assessing the safety, efficacy, and pharmacodynamics of the REGI anticoagulation system compared to unfractionated heparin or low molecular heparin in subjects with acute coronary syndrome (Radar)
• A Prospective study using the Angelmed Guardian device for Early Recognition and Treatment of STEMI study (ALERTS)
• A Phase IV Multi-center Study to compare ISOVUE250 and VISlPAQUE 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)(BRACCO)
• (Impella 2.5) Retrospective Data Registry) (US Pella)
• Endeavor Drug-eluting stenting: Understanding Care Antiplatelet agents and Thrombotic (EDUCATE)
• Prospective, Single .Blind, Randomized, Multi-Center study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus -Eluting Stent Systems( ELITE)
• Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study. (XIENCE)
• A Prospective, Randomized, Multj.Center1 Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHER Sirolimus Eluting Coronary Stent (CYPRESS).
• Biological waste material and outcomes analysis of lower extremity peripheral disease treated with the Silverhawk TM plaque extension system: A tissue and data registry. (BROADWING)
• Comparison of AL-208 vs. placebo, on mild cognitive impairment following coronary artery bypass graft surgery
• Carotid Stenting For High Surgical Risk Patients: Evaluating Outcomes Through The Collection Of Clinical Evidence (CHOICE)
• Enusre's Vascular Closure Device Speeds Hemostasis Trial: (ECLIPSE)
• Stenting and angioplasty with protection in patients at high risk for endarterectomy (SAPPHIRE)
• Carotid Acculink/Accunet Post approval Trial to Uncover unanticipated or Rare Event (CAPTURE)
David K. Roberts, MD, FACC, FSCAI
Curriculum Vitae Page 10
Updated 07/2022
CLINICAL TRIAL PARTICIPATION CONT:
Principle Investigator:
• Holmium Laser TMR Registry (TMR O 020)
• Cardioseal Starfex v Medical Rx for CVA PFO (CLOSURE I)
• Drug Eluting Stent Cover Registry (DISCOVER)
• Investigational Lipid Level RX Using IVUS Assessment of ASCAC(ILLUSTRATE)
• Comparison CS747 and Clopidogrel in ACS in .Patients Undergoing PCI(TIMI 38)
• Protection Microvascular Dysfunction Post PC1 Antithrombotic v Antiplatelet RX (PROTECT TIMI 30)
• A 12 Week Randomized Comparison Rosuvastatin & Atorvastatin in AC9 (LUNAR)
• Assessment of Pexelieumab in Acute Ml (APEX AMI)
• FilterwireEZ in AMI for Embolic protection (FLAME)
• Sirilimus Stents Vs Intracoronary Radiation for Instent Restenosis (SISR)
• Proxis Proximal Occlusion Distal Protection in SVG(PROXIMAL)
• Angioguard Distal Protection in SVG(GUARD)
• Triactive- Savenous Vein Graft Stent Distal Protection (PRIDE)
• Filterwire 2 - Savenous Vein Graft Stent Distal Protection (BLAZE I & II)
• Filterwire High Risk Registry Savenous Vein Graft Stent Distal Protection (FIREHigh Risk)
• Filterwire- Saphenous Vein Graft Stent Distal Protection (FIRE)
• Sirolimus-Eluting Stents for the Prevention of Restenosis (SIRIUS)
• Radiation Brachytherapy Superficial Femoral Artery Instent Restenosis (MOBILE)
• Stenting vs Angioplasty of Renal Artery Stenosis (HOPE)
• Hypothermia RX Acute Ml Reperfusion (COOL-MI)
• Lovenox vs Unfractionrted Heparin for Unstable Angina (SYNERGY)
• Hepacoat Stent Antithrombotic Regimen of Aspirin Alone (HOPE)
• Integrelin and TNK in Acute MI (INTEGRITI)
• BioDivYsio Stent in Randomized Controlled Trial (DISTINCT)
• Predilatation vs Direct Coronary Stenting ln Coronary Treatment Trial (PREDICT)
• Stent implantation Post Rotational Atherectomy Trial (SPORT)
• Atherectomy before Multilink Improves lumen Gain and clinical Outcomes Trial (AMIGO)
• Abciximab and Device Investigation to Lower Late Angioplasty Complications Trial (CADILLAC)
• Randomized Trial of Primary PTCA vs Heparin Coated Stent Implantation during Acute Myocardial Infarction (STENT-PAMI)
• A Randomized Trial ofT hrombolysis Compared to Transfer for Acute Intervention in High-Risk MI Patients (AIR-PAMI) with no Surgery on Site (NO S.O. S.) Registry
• The Primary PTCA in Myocardial Infarction Cardiogenic Shock Project (PAMI -SHOCK)
• Vein Graft AngioJet Trial (VeGAS 2)
• ReoPro in Acute Myocardial Infarction and Prima1y PTCA Organization and Randomized Trial (RAPPORT)
• Transluminal Extraction Coronary Atherectomy Before Stenting (TEC-BEST)
• Dilation vs Atherectomy Revascularization Trial (DART)
• Optimal Stent Implantation Trial– 2A (OSTI– 2A)
• BeStent (BEST) Stent Trial
David K. Roberts, MD, FACC, FSCAI
Curriculum Vitae Page 11
Updated 07/2022
CLINICAL TRIAL PARTICIPATION CONT:
Principle Investigator:
• Paragon Stent Trial (ACT-I)
• Optimal Angioplasty vs Stent Trial(OPUS-1)
• Eclipse Percutaneous Trans myocardial Revascularization Trial (TMR)
Co-PI and/or Sub-Investigator:
• Detennination ofSafety and Effectiveness of the SilverHawk LSC® Peripheral Plaque Excision System for Calcium (SilverHawk LS-C) and the SpiderFX Embolic Protection Device (SpiderFX) for the Treatrnent of Calcified Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries (Definitive CA++)
• A Prospective, Randomized, Controlled, Mult-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients who have Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement (PARTNER 3)
• A prospective, multicenter, single-arm study designed to assess the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk for bleeding undergoing percutaneous coronary intervention (PCI) with the SYNERG YTM Everolimus-Eluting Platinum Chromium Coronary Stent System (Evolve short DAPT)
• The "RADIANCE-HTN" Study. A study of the ReCOr Medical Paradise System in Clinical Hypertension (RADIANCE-HTN)
ADDITIONAL RESEARCH EXPIRENCE:
• Principle Investigator, Naval Hospital in Oakland, CA
Clinical Participant Fellow, Columbia University in New York, NY:
• Thrombolysis in Myocardial Infraction 2(TIMI-2)
• Late Thrombolysis in Myocardial Infarction (LATE)
• Thrombolytic Therapy in the Older Patients (TTOP)
• Thrombolysis in Pulmonary Embolism (TIPE)
• Cardiac Arrhythmia Suppression Trial 1 & 2(CAST 1&2)
Signature: Date:
David K. Roberts, MD, FACC, FSCAI